MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting

MEI Pharma, Inc. MEIP, an oncology company focused on the clinical development of novel therapies for cancer, today announced that data from the Company's Phase II clinical studies of Pracinostat in elderly acute myeloid leukemia (AML) and previously untreated myelodysplastic syndrome (MDS) have been selected by the American Society of Hematology (ASH) Program Committee for oral presentation at the 57th ASH Annual Meeting & Exposition in Orlando on December 7, 2015. Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Abstract: 453 Session: 613. Acute Myeloid Leukemia: Clinical Studies: Advances in Therapy Presentation: Monday, December 7, 2015 at 7:30 am Eastern time A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS) Abstract: 911 Session: 637. Myelodysplastic Syndromes – Clinical Studies I Presentation: Monday, December 7, 2015 at 7:15 pm Eastern time Abstracts are expected to be available at www.hematology.org on Thursday, November 5, 2015 at 9:00 am Eastern time. In addition, the abstracts will be published online in the December 3, 2015 supplemental volume of Blood.